We are live on ! Find out more
PRQR icon

ProQR Therapeutics
PRQR

35 hedge funds and large institutions have $167M invested in ProQR Therapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

36% more capital invested

Capital invested by funds: $123M → $167M (+$44.1M)

17% more funds holding

Funds holding: 30 → 35 (+5)

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
35
Holders Change
+5
Holders Change %
+16.67%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
9
Increased
11
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$13.3M
2
PC
PointState Capital
New York
+$2.63M
3
VAM
Visium Asset Management
New York
+$1.71M
4
ClearBridge Investments
ClearBridge Investments
New York
+$1.54M
5
AC
Ascend Capital
California
+$1.37M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$9.44M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$3.48M
3
DM
Deerfield Management
New York
-$2.28M
4
SM
Sabby Management
Florida
-$1.95M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$39.6M +$13.3M +879,400 +93%
JHIU
2
Janus Henderson Investors US
Colorado
$16.2M +$724K +47,687 +7%
RG
3
Redmile Group
California
$15.7M -$213K -14,061 -2%
Jennison Associates
4
Jennison Associates
New York
$12.4M -$917K -60,412 -10%
ClearBridge Investments
5
ClearBridge Investments
New York
$10.8M +$1.54M +101,617 +26%
BBA
6
Baker Bros. Advisors
New York
$8.67M – – –
DM
7
Deerfield Management
New York
$8.23M -$2.28M -150,000 -28%
Franklin Resources
8
Franklin Resources
California
$5.96M – – –
VAM
9
Visium Asset Management
New York
$5.42M +$1.71M +112,984 +82%
HCMT
10
Highland Capital Management (Texas)
Texas
$4.55M -$448K -29,507 -12%
Millennium Management
11
Millennium Management
New York
$4.55M +$877K +57,775 +38%
PC
12
PointState Capital
New York
$3.76M +$2.63M +173,500 New
FCMI
13
Foresite Capital Management II
California
$3.75M +$2.63M +173,067 New
Lord, Abbett & Co
14
Lord, Abbett & Co
New Jersey
$3.31M +$16.4K +1,080 +0.7%
SFM
15
Sphera Funds Management
Israel
$2.82M -$1.06M -70,000 -35%
Asset Management One
16
Asset Management One
Japan
$2.54M +$271K +17,830 +16%
LOAMU
17
Lombard Odier Asset Management (USA)
New York
$2.23M +$47.1K +3,105 +3%
PA
18
Perceptive Advisors
New York
$2.17M – – –
AC
19
Ascend Capital
California
$1.95M +$1.37M +90,000 New
WMSA
20
Weiss Multi-Strategy Advisers
New York
$1.72M +$715K +47,140 +147%
Principal Financial Group
21
Principal Financial Group
Iowa
$1.63M +$1.14M +75,400 New
Fidelity Investments
22
Fidelity Investments
Massachusetts
$1.57M – – –
CCM
23
Century Capital Management
Massachusetts
$1.5M +$1.05M +69,063 New
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$1.32M -$1.12M -74,115 -55%
BA
25
BlackRock Advisors
Delaware
$1.31M -$3.04K -200 -0.3%
1
2

PRQR Hedge Fund Activity: Q4 2014 in Review

35 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2014, worth a combined $167M — up 36% from $123M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PRQR positions and 4 closed out — a net gain of 5 holders — while 11 added to existing stakes and 11 trimmed.

The largest buyer was OrbiMed, adding an estimated $13.3M. The largest seller was BVF Inc, exiting entirely with an estimated $9.44M sold.

  • 35 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2014, up from 30 in Q3 2014.
  • Funds reported $167M of ProQR Therapeutics stock for Q4 2014, up 36% quarter-over-quarter.
  • 9 funds opened new ProQR Therapeutics positions in Q4 2014 and 4 closed out, a net change of +5 holders.
  • The largest ProQR Therapeutics buyer in Q4 2014 was OrbiMed, an estimated $13.3M added.
  • The largest ProQR Therapeutics seller in Q4 2014 was BVF Inc, an estimated $9.44M sold.

Based on aggregated 13F filings for Q4 2014.